These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23362548)

  • 1. [When two do the same, it is not the same. Requirements for development and quality of biosimilars].
    Rais I
    Pharm Unserer Zeit; 2012 Nov; 41(6):453-60. PubMed ID: 23362548
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars: where we were and where we are.
    Challand R; Gorham H; Constant J
    J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.
    Ghasriani H; Hodgson DJ; Brinson RG; McEwen I; Buhse LF; Kozlowski S; Marino JP; Aubin Y; Keire DA
    Nat Biotechnol; 2016 Feb; 34(2):139-41. PubMed ID: 26849514
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).
    Oldfield P
    Bioanalysis; 2011 Jul; 3(14):1551-3. PubMed ID: 21756087
    [No Abstract]   [Full Text] [Related]  

  • 5. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
    Nupur N; Chhabra N; Dash R; Rathore AS
    MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why are biosimilars much more complex than generics?
    Pagani E
    Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
    [No Abstract]   [Full Text] [Related]  

  • 8. Biosimilar medicines - Review.
    Dos Reis C; Teixo R; Mendes F; Cruz RS
    Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars.
    Vandekerckhove K; Seidl A; Gutka H; Kumar M; Gratzl G; Keire D; Coffey T; Kuehne H
    AAPS J; 2018 May; 20(4):68. PubMed ID: 29748754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
    Pani L; Montilla S; Pimpinella G; Bertini Malgarini R
    Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular copies of off-patent biologics that have become biosimilars: a new group recombinant products].
    Dingermann T; Zündorf I
    Pharm Unserer Zeit; 2012 Nov; 41(6):446-52. PubMed ID: 23362547
    [No Abstract]   [Full Text] [Related]  

  • 18. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring the Consistency of Biosimilars.
    Perez IA; Blas-Garcia A; Carmona L; Esplugues JV
    Curr Pharm Des; 2017; 23(44):6733-6738. PubMed ID: 29205112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
    Lakhanpal A; Brahn E
    Clin Rheumatol; 2016 Dec; 35(12):2869-2875. PubMed ID: 27714482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.